Is Semaglutide Effective in Children Aged 6-12 With Obesity? STEP Young Results Published in NEJM

In this article
Once-Weekly Semaglutide in Children Aged 6-12 With Obesity: What Did the STEP Young Trial Show?
The phase 3 STEP Young trial, published in the New England Journal of Medicine on November 16, 2026, showed that once-weekly subcutaneous semaglutide clearly reduced body mass index (BMI) compared with placebo in children with obesity (Turkish) aged 6-12. At week 68, BMI fell by 13.5% in the semaglutide group and rose by 2.7% in the placebo group, a difference of 16.2 percentage points. In 38% of children given semaglutide, BMI dropped below the obesity threshold, compared with 2% on placebo. However, height gain was smaller in children given semaglutide, gastrointestinal side effects were common, and the effects of the drug over the years, and what happens after it is stopped, are not yet known. Semaglutide is currently not approved for obesity under age 12 in the United States or Europe. In this article I explain the details of the trial, how to read the results, the concerns, and what it means in practice for families. I covered semaglutide use in adults in my articles on Wegovy and Ozempic (Turkish), and why obesity should be seen as a disease in this article (Turkish).
- What was studied? In 9 countries, 167 children aged 6-12 with obesity were randomized 2:1 to once-weekly semaglutide (112) or placebo (55); everyone received lifestyle counseling. Treatment lasted 104 weeks. More than 85% of the children had severe (grade 2 or 3) obesity.
- Result: At week 68, BMI change was -13.5% versus +2.7% (difference 16.2 points). BMI category improved in 79% versus 23%; dropping below the obesity threshold occurred in 38% versus 2%. At week 104 the difference persisted (-9.4% versus +8.4%). Waist circumference, blood sugar, triglycerides, and CRP also improved.
- Safety: Vomiting (70% versus 29%), diarrhea, and nausea were common; most were mild and transient. Serious adverse events were similar in both groups (9%). Height gain was smaller in the semaglutide group; bone age and pubertal development were similar.
- What does it mean? It may become an important option for young children with severe obesity in the future; but it is not yet approved, there are no long-term data, and the core treatment remains family-based lifestyle change.
Why does this matter?
More than 200 million school-age children worldwide live with obesity; in the United States, one in five children aged 6-11 has obesity. In Türkiye, a 2016 Ministry of Health study of second-grade primary school students found overweight in 14.6% and obesity in 9.9%. Childhood obesity is not just a weight problem; type 2 diabetes, high blood pressure, fatty liver, sleep apnea, joint problems, and emotional difficulties can start in childhood and worsen quickly in adulthood (insulin resistance and prediabetes, obesity and cardiovascular disease; Turkish). Obesity also raises the risk of 13 types of cancer (preventable causes of cancer, diabetes and cancer; Turkish).
Treatment options for children under 12 are very limited. Lifestyle change is the core treatment, but the average reduction in BMI is small and its durability uncertain. In the United States there is no drug approved for obesity under age 12; in the European Union only liraglutide, given as a daily injection, is approved for children aged 6 and over (liraglutide; Turkish). Young children with severe obesity and their families need effective and safe new options. On the other hand, starting a drug treatment that may last for years in growing children is a decision that needs to be weighed far more carefully than in adults.
- Yes: The first published phase 3 results of a once-weekly GLP-1 drug for treating obesity in children aged 6-12. The authors highlight the two-year placebo-controlled treatment period as one of the trial's greatest strengths.
- No: It is not the first GLP-1 drug studied in this age group; daily liraglutide was evaluated at ages 6-12 in the SCALE Kids trial published in 2025 and was approved in Europe.
- Not yet: Semaglutide is not approved for obesity under age 12 in any country; this trial is not an approval, but data that could form the basis for one.
What is the STEP Young trial?
STEP Young is a double-blind, randomized phase 3 trial that compared once-weekly subcutaneous semaglutide with placebo in 167 children aged 6-12 with obesity. The children were treated for 104 weeks, and all received lifestyle counseling. At week 68, semaglutide reduced BMI by 16.2 points more than placebo.
The trial began in July 2023 and was conducted at 48 centers in 9 countries. Children with a BMI at or above the 95th percentile for age and sex were enrolled; at least 30% of the children were required to have severe obesity. In reality the share was much higher: in the semaglutide group, 55% of the children had grade 3 obesity and 34% had grade 2. The mean age was 10, mean body weight 72 kg, and mean BMI 32.4; about half of the children had at least one obesity-related problem (such as asthma, high cholesterol, fatty liver, or prediabetes). The results therefore apply to children with severe obesity, not to children who are mildly overweight.
Figure 1 · Design of the STEP Young trial
Phase 3, double-blind, randomized, placebo-controlled
Results: weight and BMI
The primary endpoint of the trial was the percent change in BMI at week 68. In the main analysis, which evaluated all children including those who stopped treatment or switched to another treatment, BMI fell by 13.5% in the semaglutide group and rose by 2.7% in the placebo group; the difference was 16.2 points (95% CI 12.9-19.4). In the analysis that assumes children continued treatment without interruption, the reduction was 17.4%. The second figure is the one highlighted in company announcements; however, the figure that better reflects real life is 13.5%. In terms of body weight, children given semaglutide lost an average of 6.4% over 68 weeks, while the weight of children on placebo rose by 13.6%. In growing children this difference matters: the goal is not always to lose weight, but for weight not to increase, or to increase more slowly, while height grows.
Improvement by at least one BMI category was 79% in the semaglutide group and 23% in the placebo group. In 38% of children given semaglutide, BMI fell below the obesity threshold (placebo 2%), and 13% reached the healthy weight range (placebo 0%). At week 104 the difference persisted but narrowed somewhat: BMI fell by 9.4% in the semaglutide group and rose by 8.4% in the placebo group. Because the week 104 data were not adjusted for multiple comparisons, caution is needed when interpreting them (how to read research results correctly; Turkish).
Change in BMI categories
Percentage of children; according to CDC growth charts. Observed values.
Semaglutide · baseline (112)
Semaglutide · week 68 (99)
Semaglutide · week 104 (96)
Placebo · baseline (55)
Placebo · week 68 (47)
Placebo · week 104 (41)
In the semaglutide group at week 68, 38% of children fell below the obesity threshold and 13% reached the healthy weight range. In the placebo group, no child reached the healthy weight range. Percentages may not sum to 100 because of rounding.
What was the minimum BMI reduction at week 68?
Percentage of children; semaglutide (colored) and placebo (gray).
These results are supportive endpoints and were not adjusted for multiple comparisons; they should not be interpreted as precise effect sizes.
Cardiometabolic indicators and body composition
At week 68, waist circumference fell by 8.5 cm in the semaglutide group and rose by 2.7 cm in the placebo group. Systolic blood pressure, HbA1c, triglycerides, and the inflammation marker CRP also fell more with semaglutide; for example, CRP fell by 68% (placebo 14%). In a prespecified exploratory analysis, blood sugar returned to normal at week 68 in 93% of children who had prediabetes at baseline (placebo 56%) (prediabetes; Turkish). These results are promising, but because they were not adjusted for multiple comparisons, they should be considered supportive findings, not definitive evidence (cholesterol; Turkish).
Body composition was measured by DXA in 50 children. In the semaglutide group, the percentage of body fat fell more and the proportion of lean tissue rose more. In absolute terms, however, lean mass rose more in children in the placebo group (5.3 kg versus 3.1 kg at week 68). The authors attribute this to the overall weight gain in the placebo group; even so, monitoring muscle and bone development during the growth years is important (weight-loss injections and muscle loss; Turkish).
Safety: height, gut, and mental health
Height growth
The most notable safety finding of the trial was height gain. The median height gain at week 68 was 5.7 cm in the semaglutide group and 7.8 cm in the placebo group; at week 104, 8.8 cm versus 12.1 cm. The annual growth rate was also lower with semaglutide. In contrast, bone age, bone mineral density, and pubertal development were similar in the two groups. The authors think that children with obesity grow faster than normal before puberty and that growth velocity may have moved closer to normal as weight fell. This explanation is plausible; but years of follow-up are needed to know the effect on final adult height.
Gastrointestinal side effects
Side effects were very common in both groups (96% versus 93%). The most common were gastrointestinal and occurred more often with semaglutide: through week 111, vomiting 70% versus 29%, diarrhea 62% versus 35%, nausea 58% versus 24%. These side effects were mostly mild to moderate and transient, and were concentrated in the dose-escalation period; only 1 child stopped treatment for this reason. The fact that vomiting is more common in children than in adults is notable (side effects of weight-loss injections; Turkish). Serious adverse events were similar in both groups (9%), no loss of life was recorded, and no new safety signal was identified.
Side effects (through week 111)
Percentage of children; semaglutide (colored) and placebo (gray).
Gastrointestinal side effects were mostly mild to moderate and transient, and were concentrated in the dose-escalation period; for this reason 1 child stopped treatment. Overall discontinuation because of side effects was 4% in the semaglutide group and 2% in the placebo group. There was no loss of life.
Mental health
A mental health symptom or diagnosis was reported in 21% of children in the semaglutide group and 24% in the placebo group; referral to a mental health specialist was also lower in the semaglutide group (8% versus 15%). These findings do not support concerns that GLP-1 drugs harm mental health (little-known side effects of weight-loss injections; Turkish). However, the trial did not screen for eating disorders (weight-loss injections and eating behavior; Turkish); the long-term effects on children's eating behavior of a drug that markedly suppresses appetite need to be studied separately.
Figure 2 · Points to keep in mind when reading the results
Benefit, uncertainty, and limits
Comparison with other studies
| Study | Age, drug | Duration | BMI change (drug / placebo) |
|---|---|---|---|
| STEP Young (2026) | Ages 6-12, once-weekly semaglutide | 68 weeks | -13.5% / +2.7%; difference 16.2 points |
| SCALE Kids (2025) | Ages 6-12, daily liraglutide | 56 weeks | Difference 7.4 points |
| STEP TEENS (2022) | Ages 12-18, once-weekly semaglutide | 68 weeks | -16.1% / +0.6%; difference 16.7 points |
| Lifestyle change | Various ages | Variable | Average reduction of about 0.7 units in BMI |
The studies were not compared directly; however, the table suggests that the effect at ages 6-12 is close to that seen in adolescents and larger than with daily liraglutide. I covered the use of semaglutide and tirzepatide in adults in my articles on the real-world effects of weight-loss injections (Turkish) and on tirzepatide (Turkish).
What it means in practice for families
This trial shows that a door has opened a crack for young children with severe obesity; but it is not yet a treatment recommendation. Semaglutide is not approved for obesity under age 12 in any country; use in this age group would be off-label and could be considered only in exceptional cases under the close supervision of pediatric endocrinologists. A child should not be started on a weight-loss injection based on information from the internet or those around them.
Figure 3 · A stepwise approach to childhood obesity
The drug goes alongside core treatment, not in place of it
My most important message to families is this: childhood obesity is not a "lack of willpower" on the part of the child or the family, but a chronic disease that needs treatment. The core treatment is to organize nutrition, physical activity, sleep, and screen time, with the whole family taking part (children and sport, neighborhood games, the basics of nutrition; Turkish). Drugs are tools that, in the age groups for which they are approved and in suitable children, can be added alongside this foundation, not in place of it. Avoiding stigmatizing language about a child's weight and talking about the child's health and well-being is also part of treatment (the real cause of obesity; Turkish).
The situation in Türkiye
In Türkiye, semaglutide (Wegovy) is licensed for obesity treatment and sold in pharmacies; however, it is not reimbursed by the social security system (SGK), and it has no approved use for obesity treatment in children under 12 (can weight loss reverse diabetes?; Turkish). In a country where childhood obesity is steadily rising, strengthening school- and family-based prevention programs and referring children with severe obesity early to pediatric endocrinology centers are the highest-priority steps, regardless of new drugs (what obesity means, diabetes and Türkiye; Turkish).
Questions you can ask your child's doctor
- At what percentile is my child's BMI for age and sex, and what is the degree of obesity?
- Is there an obesity-related problem (prediabetes, fatty liver, blood pressure, sleep apnea)?
- Should a genetic or hormonal cause be investigated?
- What changes should we make as a family; is referral to a dietitian or a pediatric obesity program possible?
- Is drug treatment an option at my child's age and in my child's situation; or might a clinical trial be suitable (what is a clinical trial?; Turkish)?
- "Weight-loss injections can now be given to children too." No. Semaglutide is not approved for obesity under age 12; this trial is data that could form the basis for approval.
- "If the injection is started, diet and exercise are not needed." Wrong. All the children in the trial also received lifestyle counseling; the drug does not replace this foundation.
- "If a child doesn't lose weight, the treatment has failed." In growing children, keeping weight steady or letting it rise slowly lowers BMI as height grows; the goal is not always weight loss.
- "This drug makes a child shorter." Height gain was smaller with semaglutide, but bone age and pubertal development were similar; the effect on final height is unknown and follow-up is needed.
- "Childhood obesity goes away as the child grows up." In most children with severe obesity, the obesity persists into adulthood and health problems start early.
Frequently Asked Questions
- What is the STEP Young trial?
- STEP Young is a phase 3 trial that compared once-weekly subcutaneous semaglutide with placebo in 167 children aged 6-12 with obesity. At week 68, BMI fell by 13.5% in the semaglutide group and rose by 2.7% in the placebo group. The results were published in the New England Journal of Medicine on November 16, 2026.
- Can semaglutide be used in children?
- Semaglutide is approved for treating obesity in adolescents aged 12 and over. It is not yet approved in any country for children aged 6-12. In this age group, the decision to use it can be made only by pediatric endocrinologists, in exceptional cases.
- What are the side effects of semaglutide in children?
- The most common side effects are vomiting, diarrhea, and nausea; most are mild and transient. In STEP Young, vomiting occurred in 70% with semaglutide and 29% with placebo. Height gain was smaller in children given semaglutide; bone age and pubertal development were similar.
- How is childhood obesity treated?
- The core treatment is lifestyle therapy covering nutrition, physical activity, sleep, and screen time, with the whole family taking part. In severe obesity a pediatric endocrinology evaluation is needed; drugs approved at age 12 and over can be added to this treatment in suitable children.
Glossary
- BMI (body mass index)
- A value calculated by dividing weight by height squared; in children it is assessed by percentile for age and sex.
- Percentile
- A child's rank among 100 children of the same age and sex.
- Severe obesity
- A child's BMI at 120% or more of the 95th percentile value (grade 2 and 3 obesity).
- GLP-1 receptor agonist
- A group of drugs that mimic a gut hormone, reduce appetite, and regulate blood sugar.
- Semaglutide
- A GLP-1 receptor agonist given subcutaneously once a week.
- Liraglutide
- A GLP-1 receptor agonist given once a day; approved in Europe for obesity in children aged 6 and over.
- Placebo
- A drug that looks identical but contains no active ingredient.
- DXA
- A low-dose X-ray scan that measures the amount of fat, muscle, and bone in the body.
- Tanner stage
- A grading of pubertal development from 1 to 5.
- Off-label use
- Using a drug at an age or in a situation for which it is not approved.
DROZDOGAN Academy Commentary
STEP Young shows the most effective drug results to date in young children with severe obesity. But starting a drug that may last for years in a growing child raises far more questions than in an adult; some of these questions do not yet have answers.
⚡ Why it matters
At ages 6-12, there were almost no effective options for severe obesity. A 16-point BMI difference and more than a third of children dropping below the obesity threshold carry significant potential for preventing early-onset diabetes, liver, and cardiovascular problems in these children.
✅ Strengths
A double-blind, placebo-controlled, two-year phase 3 design; a realistic group of patients with severe obesity; body composition measured by DXA; detailed monitoring of growth, bone age, and pubertal development; full publication in a peer-reviewed journal.
⚠️ Limits
Small sample (167 children); most participants white; no eating disorder screening; high discontinuation in the placebo group; only 7 weeks of follow-up after the drug was stopped; the effect of the reduced height gain on final height is unknown; company-sponsored trial.
🩺 In practice
I am a medical oncologist; but knowing that obesity raises cancer risk, I follow this topic closely. To families who consult me about their child's weight, I first recommend a pediatrician and pediatric endocrinology evaluation and family-based lifestyle therapy. Even if semaglutide is approved in this age group, I believe the decision should be made by an experienced pediatric team that also monitors growth and mental health.
❓ Open questions
Will weight come back when the drug is stopped? How many years should treatment last? How will final adult height, bone health, and puberty be affected? What is the long-term effect on eating behavior? Will treatment started at a young age reduce the risk of diabetes, heart disease, and cancer in adulthood?
Bottom line: STEP Young is an important trial showing that semaglutide reduces BMI markedly, and over two years, in children aged 6-12 with severe obesity. But it is not yet an approval; until long-term safety and durability data arrive, the core treatment in this age group should remain family-based lifestyle change.
- This article was prepared in November 2026.
- The data are based on the New England Journal of Medicine article dated November 16, 2026. The main analysis is the one that includes all children, including those who stopped treatment; the 17.4% BMI reduction highlighted in company announcements belongs to the analysis that assumes children continued treatment without interruption.
- The week 104 results, cardiometabolic measurements, and BMI reduction thresholds were not adjusted for multiple comparisons; they should not be interpreted as precise effect sizes.
- The trial was sponsored by Novo Nordisk. Türkiye's childhood obesity data are taken from the Ministry of Health's 2016 study.
- The diagrams are simplified. The Academy commentary is my own. This article is not medical advice; make decisions about your child's treatment together with your child's doctor.
Sources
- Jastreboff AM, Harder-Lauridsen NM, Van Name M, et al. Semaglutide for the Treatment of Obesity in Children 6 to <12 Years of Age. N Engl J Med 2026. nejm.org
- Novo Nordisk. STEP Young results presented at ObesityWeek 2026 (16 November 2026). novonordisk.com
- Fox CK, Barrientos-Pérez M, Bomberg EM, et al. Liraglutide for children 6 to <12 years of age with obesity — a randomized trial. N Engl J Med 2025;392:555-565. pubmed
- Weghuber D, Barrett T, Barrientos-Pérez M, et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med 2022;387:2245-2257. doi
- Hampl SE, Hassink SG, Skinner AC, et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity. Pediatrics 2023;151:e2022060640. doi
- Contemporary Pediatrics. Semaglutide cuts BMI 13.5% in children aged 6 to 11 with obesity (16 November 2026). contemporarypediatrics.com
- Republic of Türkiye Ministry of Health. Türkiye Childhood Obesity Study (COSI-TUR) report. hsgm.saglik.gov.tr
Was this article helpful?
Your feedback helps us improve our content.




